Form 4: BioMarin Director Barbara Bodem Acquires 6,650 Shares of Common Stock
SEC Form 4
Director Barbara W. Bodem acquired 6,650 shares of BioMarin Pharmaceutical Inc. common stock on May 20, 2025, through restricted stock units.
Summary
- On May 20, 2025, Barbara W. Bodem, a director of BioMarin Pharmaceutical Inc., acquired 6,650 shares of common stock.
- The acquisition was through the grant of restricted stock units.
- The reporting person's direct holdings have been adjusted by five shares to correct a previous clerical error.
- Following the transaction, Bodem directly owns 13,555 shares of BioMarin common stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Barbara W. Bodem acquired 6,650 shares of BioMarin common stock through restricted stock units. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
Keywords
BioMarin, Director, Bodem, Stock Acquisition, Restricted Stock Units, BMRN, Common Stock, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.